Ultra-Long Peripheral Catheter Versus Accelerated Seldinger Technique Long Peripheral Catheter in Difficult IV Access Patients
ULAST
Ultra Long Peripheral Catheter Versus Accelerated Seldinger Technique Long Peripheral Catheter in Difficult Intravenous Access Patients: a Pragmatic Randomised Controlled Trial
1 other identifier
interventional
100
1 country
1
Brief Summary
The aim of this study is to perform a comparative analysis of clinical outcomes associated with the use of an ultra-long peripheral catheter using (catheter-over-the-needle technique) versus an AST-long peripheral catheter in adult patients with difficult intravenous access (DIVA) in a real-world clinical setting. Specifically, the study will assess potential benefits, including longer mean catheter dwell time and improved catheter usability, as well as potential harms, such as increased incidence of catheter-related thrombosis, infections, phlebitis, infiltration, and unplanned catheter removal.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jul 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 14, 2025
CompletedFirst Posted
Study publicly available on registry
June 5, 2025
CompletedStudy Start
First participant enrolled
July 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
April 30, 2026
CompletedJune 5, 2025
June 1, 2025
10 months
May 14, 2025
June 2, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Dwell time
is defined as the duration between the date of catheter insertion and the date of its removal, expressed in hours.
Until study completion, an average of 14 days.
Secondary Outcomes (5)
Number of Participants with Catheter related thrombosis
Until study completion, an average of 14 days.
Number of Participants with Midline catheter related infections
Until study completion, an average of 14 days.
Number of Participants with Phlebitis
Until study completion, an average of 14 days.
Number of Participants with Loss of catheter usability
Until study completion, an average of 14 days.
Number of Participants with Unplanned removal
Until study completion, an average of 14 days.
Study Arms (2)
Accelerated seldinger technique LPC
ACTIVE COMPARATOROne study arm will be assigned the AST-long peripheral catheter (Powerglide Pro long peripheral catheter, BD) available in 18G 100 mm, 20G 100 mm (approx. 3.94 inches) and 22G 80 mm (approx. 3.15 inches).
Ultra-long peripheral catheter
EXPERIMENTALThe other study arm will be assigned the ultralong peripheral catheter (Introcan Safety deep access catheter, B. Braun) available in 18, 20 and 22G and 63.5 mm (approx. 2.5 inches) in length.
Interventions
A long peripheral catheter will be placed under ultrasound guidance. This catheter will be placed by using the Accelerated seldinger technique.
The catheter will be placed using ultrasound guidance and by using the 'catheter-over-the needle' approach.
Eligibility Criteria
You may qualify if:
- Adult inpatients with DIVA, requiring placement of a long peripheral catheter, will be included in the study.
- A digital request form for venous access must be completed by the treating physician at the ward.
- Patients must be proficient in either Dutch or French
- Patients must have decision-making capacity or be represented by a legal representative.
You may not qualify if:
- Expected therapy duration of less than 24 hours
- pregnancy
- Need for central venous access
- Inability to locate a deep peripheral vein in the upper extremity prior enrollment in the study
- Veins located deeper than 1.6cm prior enrollment in the study
- withdrawal of consent, or presentation at a time when study personnel are unavailable.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University Ghentlead
Study Sites (1)
Universitair ziekenhuis Brussel
Brussels, Jette, 1090, Belgium
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof. Dr.
Study Record Dates
First Submitted
May 14, 2025
First Posted
June 5, 2025
Study Start
July 1, 2025
Primary Completion
April 30, 2026
Study Completion
April 30, 2026
Last Updated
June 5, 2025
Record last verified: 2025-06
Data Sharing
- IPD Sharing
- Will not share
The data is confidential.